Literature DB >> 6291564

Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure.

S Ricci, P Zaniol, V Teglio, P Baraldi, G Mattioli.   

Abstract

1 The angiotensin-converting-enzyme inhibitor captopril is known to produce beneficial haemodynamic effects in patients with chronic congestive heart failure. 2 Twelve patients with chronic congestive heart failure were conventionally treated with digitalis and diuretic therapy plus oral captopril (75-150 mg/day), and 14 patients were used as a control group. 3 There was no improvement in functional and haemodynamic values in the controls, but the patients treated with captopril showed a significant functional improvement (increase of exercise time and improvement in New York Heart Association functional class), a definitive decrease in systemic vascular resistance (20%), and a significant increase in the cardiac index and ejection fraction (18% and 28% respectively).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6291564      PMCID: PMC1427523          DOI: 10.1111/j.1365-2125.1982.tb02079.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  45 in total

1.  Angiotensin converting enzyme inhibition: a new therapeutic modality.

Authors:  H Gavras; F Charocopos; H Brunner; I Gavras
Journal:  Bull N Y Acad Med       Date:  1981-05

Review 2.  Anti-renin system therapy. A new horizon for understanding and treating hypertension.

Authors:  J H Laragh
Journal:  Am Heart J       Date:  1981-03       Impact factor: 4.749

3.  Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captopril.

Authors:  R K Ferguson; P H Vlasses
Journal:  Am Heart J       Date:  1981-05       Impact factor: 4.749

4.  Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure.

Authors:  T B Levine; J A Franciosa; J N Cohn
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

5.  Hemodynamic and volume changes associated with captopril.

Authors:  R C Tarazi; E L Bravo; F M Fouad; P Omvik; R J Cody
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

6.  Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure.

Authors:  N A Awan; M K Evenson; K E Needham; A Win; D T Mason
Journal:  Am Heart J       Date:  1981-01       Impact factor: 4.749

7.  Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure.

Authors:  V J Dzau; W S Colucci; G H Williams; G Curfman; L Meggs; N K Hollenberg
Journal:  N Engl J Med       Date:  1980-06-19       Impact factor: 91.245

Review 8.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

9.  Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy.

Authors:  D P Faxon; J L Halperin; M A Creager; H Gavras; E C Schick; T J Ryan
Journal:  Am Heart J       Date:  1981-05       Impact factor: 4.749

10.  Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment.

Authors:  D N Sharpe; J E Douglas; R J Coxon; B Long
Journal:  Lancet       Date:  1980-11-29       Impact factor: 79.321

View more
  1 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.